XNW5004 tablets

DRUG3 trials

Sponsors

Evopoint Biosciences Inc.

Conditions

Advanced TumorFollicular Lymphoma Grade 3AFollicular Lymphoma, Grade 1Follicular Lymphoma, Grade 2Follicular Lymphoma, Grade 3LymphomaRelapsed/Refractory Peripheral T Cell Lymphoma

Phase 1

To Evaluate a Phase I/II Clinical Study of XNW5004 Tablets in Patients With Relapsed/Refractory Advanced Tumors

CompletedNCT06558513

Evopoint Biosciences Inc.Advanced Tumor, Lymphoma

Start: 2021-08-03End: 2025-08-30Updated: 2026-01-12

Phase 2

To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma

Not yet recruitingNCT06702605

Evopoint Biosciences Inc.Relapsed/Refractory Peripheral T Cell Lymphoma

Start: 2024-11-30End: 2027-01-31Target: 50Updated: 2024-11-25

Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma

RecruitingNCT07545603

Evopoint Biosciences Inc.Follicular Lymphoma, Grade 1, Follicular Lymphoma, Grade 2, Follicular Lymphoma, Grade 3 +1

Start: 2026-02-14End: 2028-12-31Target: 65Updated: 2026-04-22

Related Papers

A phase 1/2 study to evaluate the safety and efficacy of XNW5004, a selective EZH2 inhibitor, in subjects with relapsed/refractory non-Hodgkin lymphoma.

Journal of Clinical Oncology2025-05-281 citations